INS and Alzheimer disease: Brain insulin resistance emerges as a pathological hallmark of AD, leading to dysregulation in metabolism, inflammation, oxidative stress, impaired insulin signalling, mitochondrial dysfunction and synaptic dysfunction [66–68].